PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
| News Release |
FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
27 February 2008 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. PRESENTS AT THE
SOUTHEAST VENTURE CONFERENCE 2008
IN TYSONS CORNER, VIRGINIA
(Charlottesville, VA, February 28, 2008) – PluroGen Therapeutics, Inc. today announced it presented at the
Southeast Venture Conference (SEVC) 2008 in Tysons Corner, Virginia.
Commenting on the presentation, Neal G. Koller, President & CEO of PluroGen said “Plurogen is very privileged to
have been one of only 40 companies chosen to present at this premier investment conference. The contacts we
made and the publicity and interest we received have been invaluable. Attendance at this year’s conference
nearly doubled that of last year providing Plurogen terrific exposure to the investment and corporate
communities.”
About PluroGen Therapeutics, Inc.
Headquartered in Charlottesville, Va., PluroGen is a wound healing company commercializing its patent-protected
gel technology platform that provides superior and differentiated physical and bio-active benefits to wound
healing. The platform delivers drug and non-drug compounds as protected and advanced therapeutic products
for simple and complex wound healing. PluroGen’s product pipeline targets improved, protected therapies for the
6 Areas of Therapeutic Treatment of tissue healing (cleansing, infection, pain, inflammation, tissue salvage, tissue
regeneration).
The company’s first two products, PluroGel™ Silver Sulfadiazine and PluroGel™ TAG, are topical antimicrobial
products. Currently in routine use, PluroGel™ TAG is showing superior results at the University of Virginia Medical
Center on more than 2,000 patients, both chronic wound and burn. PluroGen’s management team, operational
partners, Boards and Principal Investigators are recognized global clinical and commercial leaders in PluroGen’s
target markets of wound care and burn care and in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
About Southeast Venture Conference 2008
The Southeast Venture Conference (SEVC) showcases the most promising emerging technology firms in the
southeast region and provides these companies with unmatched exposure to the region's top venture capitalists
and private equity investors. The SEVC strives to support entrepreneurial activity, innovation, and the resultant
economic development of the Southeast, while understanding the importance of investment capital to those
goals. Presented by TechJournal South, the business publication of the southeast's technology community, the
SEVC promotes networking and interaction among the leaders of tomorrow's economy. The SEVC will showcase
companies from all technology sectors.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking
statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and
which are identified from time to time in the Company’s reports filed with the U.S. Securities and Exchange
Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise.
President & CEO
27 February 2008 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. PRESENTS AT THE
SOUTHEAST VENTURE CONFERENCE 2008
IN TYSONS CORNER, VIRGINIA
(Charlottesville, VA, February 28, 2008) – PluroGen Therapeutics, Inc. today announced it presented at the
Southeast Venture Conference (SEVC) 2008 in Tysons Corner, Virginia.
Commenting on the presentation, Neal G. Koller, President & CEO of PluroGen said “Plurogen is very privileged to
have been one of only 40 companies chosen to present at this premier investment conference. The contacts we
made and the publicity and interest we received have been invaluable. Attendance at this year’s conference
nearly doubled that of last year providing Plurogen terrific exposure to the investment and corporate
communities.”
About PluroGen Therapeutics, Inc.
Headquartered in Charlottesville, Va., PluroGen is a wound healing company commercializing its patent-protected
gel technology platform that provides superior and differentiated physical and bio-active benefits to wound
healing. The platform delivers drug and non-drug compounds as protected and advanced therapeutic products
for simple and complex wound healing. PluroGen’s product pipeline targets improved, protected therapies for the
6 Areas of Therapeutic Treatment of tissue healing (cleansing, infection, pain, inflammation, tissue salvage, tissue
regeneration).
The company’s first two products, PluroGel™ Silver Sulfadiazine and PluroGel™ TAG, are topical antimicrobial
products. Currently in routine use, PluroGel™ TAG is showing superior results at the University of Virginia Medical
Center on more than 2,000 patients, both chronic wound and burn. PluroGen’s management team, operational
partners, Boards and Principal Investigators are recognized global clinical and commercial leaders in PluroGen’s
target markets of wound care and burn care and in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
About Southeast Venture Conference 2008
The Southeast Venture Conference (SEVC) showcases the most promising emerging technology firms in the
southeast region and provides these companies with unmatched exposure to the region's top venture capitalists
and private equity investors. The SEVC strives to support entrepreneurial activity, innovation, and the resultant
economic development of the Southeast, while understanding the importance of investment capital to those
goals. Presented by TechJournal South, the business publication of the southeast's technology community, the
SEVC promotes networking and interaction among the leaders of tomorrow's economy. The SEVC will showcase
companies from all technology sectors.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking
statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and
which are identified from time to time in the Company’s reports filed with the U.S. Securities and Exchange
Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise.